GlassScriptPhysician profile
James C Shaya
NPI 1659307619
$2,875.73
in general payments reported to CMS, 2019-2025
25 companies · $306 in 2025
The $306 reported for 2025 was more than what 85% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $431 · 2020: $84.17 · 2021: $224 · 2022: $559 · 2023: $518 · 2024: $753 · 2025: $306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,577.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $497.52 | 2019-2024 | Jornay Pm |
| Corium, LLC | $351.89 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $319.19 | 2021-2024 | Qelbree, Qelbree |
| Merck Sharp & Dohme LLC | $293.39 | 2020-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Tris Pharma INC | $236.33 | 2019-2025 | Dyanavel Xr |
| Alk-Abello, INC | $152.44 | 2023-2025 | Grastek, Odactra, Ragwitek |
| Kaleo, INC. | $130.82 | 2021-2023 | Auvi-Q |
| Sanofi Pasteur INC. | $121.32 | 2019-2023 | |
| Collegium Pharmaceutical, INC. | $114.73 | 2025 | Jornay Pm |
| Pfizer INC. | $92.01 | 2019-2023 | |
| Genentech USA, INC. | $91.19 | 2019-2022 | |
| Aytu Biopharma, INC. | $61.92 | 2019-2020 | |
| Cranial Technologies, INC | $58.00 | 2019-2023 | Doc Band |
| Glaxosmithkline, LLC. | $50.32 | 2019-2023 | Bexsero |
| Takeda Pharmaceuticals U.S.A., INC. | $49.73 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $44.05 | 2019 | |
| Adlon Therapeutics L.P. | $42.35 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $41.62 | 2019 | |
| Neurocrine Biosciences, INC. | $23.37 | 2024 | |
| Avion Pharmaceuticals | $21.49 | 2023 | Methylphenidate Hydrochloride |
| Neos Therapeutics, LP | $20.77 | 2024 | Cotempla Xr-Odt |
| Seqirus USA INC | $19.86 | 2022 | |
| Verrica Pharmaceuticals INC. | $18.21 | 2024 | Ycanth |
| Mylan Pharmaceuticals INC. | $12.16 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Shaya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.